Contributions
Minorities Under-represented in Key Clinical Trials Used in Novel Drug Approvals
A large multi-national study analyzing data from 1993-2013 has concluded that minority underrepresentation is a recurring problem in clinical trials for novel agents to treat prostate cancer. This may have implications in clinical efficacy in minority populations while using those novel agents that were approved based on these under representative studies. Prostate cancer (PCa) incidence...